Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma

NCT01235793 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT01235793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
October 14, 2010
Completion date
April 18, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma originating in the cns